Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Charles River Laboratories International's average EBITDA Per Share Growth Rate was -56.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -24.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -10.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Charles River Laboratories International was 19.30% per year. The lowest was -24.50% per year. And the median was 9.10% per year.
Charles River Laboratories International (NYSE:CRL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Charles River Laboratories International 3-Year EBITDA Growth Rate Related Terms
CRL vs RVTY, ICLR, QGEN: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's 3-Year EBITDA Growth Rate falls into.
Charles River Laboratories International 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -24.50% mean?
Charles River Laboratories International (CRL) has a 3-Year EBITDA Growth Rate of -24.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Charles River Laboratories International and its competitors. According to the industry distribution chart, Charles River Laboratories International ranks #144 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 87.8%.
Is Charles River Laboratories International's 3-Year EBITDA Growth Rate too high?
Charles River Laboratories International's current 3-Year EBITDA Growth Rate is -24.50%. Based on the distribution chart, Charles River Laboratories International ranks #144 out of 164 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Charles River Laboratories International has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's 3-Year EBITDA Growth Rate compare to RVTY and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #144 out of 164 companies for 3-Year EBITDA Growth Rate. This places Charles River Laboratories International in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.30, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current 3-Year EBITDA Growth Rate is -24.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is $194.36, compared to a current price of $280.05 — trading 44.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -24.50%. Charles River Laboratories International's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current 3-Year EBITDA Growth Rate is -24.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $280.05 is trading 44.1% above its estimated GF Value™ of $194.36.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for CRL:
3-Year EBITDA Growth Rate: -24.50%
GF Value™: $194.36 vs. price of $280.05 (44.1% above fair value)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
74GF Score
Get the complete analysis for CRL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
